| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 65 | 2023 | 5100 | 7.050 |
Why?
|
| Kruppel-Like Transcription Factors | 18 | 2018 | 271 | 5.400 |
Why?
|
| Carcinoma, Pancreatic Ductal | 20 | 2023 | 1754 | 4.820 |
Why?
|
| Forkhead Transcription Factors | 21 | 2018 | 777 | 4.640 |
Why?
|
| Sp1 Transcription Factor | 17 | 2013 | 188 | 3.580 |
Why?
|
| Stomach Neoplasms | 27 | 2023 | 2281 | 2.990 |
Why?
|
| Neoplasm Metastasis | 43 | 2018 | 5124 | 2.430 |
Why?
|
| Nitric Oxide Synthase | 23 | 2005 | 316 | 2.360 |
Why?
|
| Gene Expression Regulation, Neoplastic | 48 | 2023 | 8882 | 2.200 |
Why?
|
| Neovascularization, Pathologic | 28 | 2015 | 1545 | 2.150 |
Why?
|
| Nitric Oxide | 21 | 2010 | 644 | 2.100 |
Why?
|
| Mice, Nude | 61 | 2018 | 4303 | 2.010 |
Why?
|
| Pancreas | 10 | 2023 | 717 | 1.990 |
Why?
|
| Signal Transduction | 37 | 2023 | 11972 | 1.850 |
Why?
|
| Forkhead Box Protein M1 | 21 | 2017 | 112 | 1.760 |
Why?
|
| Adenocarcinoma | 29 | 2018 | 7793 | 1.550 |
Why?
|
| Mice | 103 | 2023 | 34393 | 1.500 |
Why?
|
| Animals | 129 | 2023 | 59489 | 1.490 |
Why?
|
| Plicamycin | 5 | 2011 | 30 | 1.430 |
Why?
|
| Cell Line, Tumor | 53 | 2022 | 14561 | 1.330 |
Why?
|
| Vascular Endothelial Growth Factor A | 24 | 2011 | 1534 | 1.320 |
Why?
|
| Epithelial-Mesenchymal Transition | 8 | 2018 | 973 | 1.300 |
Why?
|
| Interleukin-8 | 11 | 2004 | 520 | 1.270 |
Why?
|
| Carcinogenesis | 7 | 2023 | 1027 | 1.270 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 5 | 2023 | 385 | 1.190 |
Why?
|
| Promoter Regions, Genetic | 29 | 2018 | 3076 | 1.190 |
Why?
|
| Neoplasm Invasiveness | 21 | 2017 | 3983 | 1.170 |
Why?
|
| Transfection | 34 | 2015 | 2934 | 1.150 |
Why?
|
| Neoplastic Stem Cells | 7 | 2018 | 1439 | 1.140 |
Why?
|
| Disease Progression | 21 | 2019 | 6693 | 1.080 |
Why?
|
| Mice, Inbred BALB C | 30 | 2018 | 2344 | 1.070 |
Why?
|
| Colonic Neoplasms | 9 | 2012 | 1389 | 1.020 |
Why?
|
| Cell Proliferation | 25 | 2023 | 7241 | 1.010 |
Why?
|
| Receptors, Calcitriol | 3 | 2015 | 133 | 0.990 |
Why?
|
| Tumor Cells, Cultured | 41 | 2018 | 5378 | 0.990 |
Why?
|
| Acinar Cells | 3 | 2023 | 53 | 0.970 |
Why?
|
| Transcriptional Activation | 13 | 2019 | 1068 | 0.970 |
Why?
|
| Blotting, Western | 19 | 2015 | 3529 | 0.970 |
Why?
|
| Neoplasm Transplantation | 18 | 2018 | 1516 | 0.970 |
Why?
|
| Cell Transformation, Neoplastic | 12 | 2023 | 2362 | 0.960 |
Why?
|
| Tissue Array Analysis | 8 | 2015 | 762 | 0.960 |
Why?
|
| Glycolysis | 3 | 2019 | 523 | 0.920 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 2 | 2014 | 107 | 0.890 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2014 | 300 | 0.880 |
Why?
|
| RNA-Binding Proteins | 5 | 2016 | 984 | 0.870 |
Why?
|
| STAT3 Transcription Factor | 9 | 2016 | 1122 | 0.860 |
Why?
|
| Pancreatic Diseases | 1 | 2023 | 108 | 0.850 |
Why?
|
| Triterpenes | 2 | 2013 | 64 | 0.840 |
Why?
|
| Humans | 152 | 2023 | 262248 | 0.830 |
Why?
|
| Liver Neoplasms | 14 | 2023 | 4563 | 0.820 |
Why?
|
| Cell Movement | 16 | 2022 | 2462 | 0.790 |
Why?
|
| Arginine | 4 | 2020 | 498 | 0.780 |
Why?
|
| Immunohistochemistry | 22 | 2018 | 7545 | 0.770 |
Why?
|
| Pancreatitis | 1 | 2023 | 269 | 0.750 |
Why?
|
| Angiogenesis Inhibitors | 6 | 2015 | 1247 | 0.740 |
Why?
|
| Retinoblastoma-Binding Protein 2 | 1 | 2019 | 5 | 0.720 |
Why?
|
| Pancreatic Ducts | 2 | 2022 | 122 | 0.710 |
Why?
|
| Transcription Factors | 11 | 2018 | 5253 | 0.700 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2020 | 160 | 0.700 |
Why?
|
| Monocarboxylic Acid Transporters | 1 | 2019 | 44 | 0.690 |
Why?
|
| Heterografts | 8 | 2018 | 734 | 0.690 |
Why?
|
| Endothelial Growth Factors | 7 | 2003 | 197 | 0.690 |
Why?
|
| Transcription, Genetic | 15 | 2019 | 3127 | 0.690 |
Why?
|
| Stromal Cells | 2 | 2014 | 815 | 0.690 |
Why?
|
| Core Binding Factor Alpha 3 Subunit | 3 | 2008 | 32 | 0.680 |
Why?
|
| Lymphokines | 7 | 2003 | 268 | 0.680 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2019 | 75 | 0.670 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2013 | 600 | 0.660 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2020 | 1493 | 0.660 |
Why?
|
| Hyaluronan Receptors | 2 | 2018 | 249 | 0.650 |
Why?
|
| DNA-Binding Proteins | 9 | 2018 | 4787 | 0.640 |
Why?
|
| Nitric Oxide Synthase Type II | 15 | 2006 | 261 | 0.640 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2018 | 34 | 0.640 |
Why?
|
| Carcinoma in Situ | 1 | 2022 | 485 | 0.640 |
Why?
|
| Up-Regulation | 14 | 2016 | 2450 | 0.630 |
Why?
|
| Pyruvic Acid | 1 | 2019 | 132 | 0.630 |
Why?
|
| Xenograft Model Antitumor Assays | 14 | 2020 | 3818 | 0.620 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2018 | 81 | 0.620 |
Why?
|
| Gastric Mucosa | 7 | 2011 | 613 | 0.620 |
Why?
|
| RNA, Small Interfering | 12 | 2019 | 2215 | 0.620 |
Why?
|
| Membrane Proteins | 4 | 2019 | 2811 | 0.610 |
Why?
|
| Protein Isoforms | 4 | 2018 | 836 | 0.590 |
Why?
|
| Precancerous Conditions | 2 | 2016 | 1063 | 0.590 |
Why?
|
| Glucose | 3 | 2023 | 1247 | 0.570 |
Why?
|
| RNA, Long Noncoding | 3 | 2018 | 601 | 0.560 |
Why?
|
| Metaplasia | 3 | 2022 | 385 | 0.550 |
Why?
|
| Female | 74 | 2022 | 142293 | 0.540 |
Why?
|
| Apoptosis | 16 | 2018 | 7601 | 0.530 |
Why?
|
| RNA, Messenger | 22 | 2022 | 6129 | 0.530 |
Why?
|
| Neurofibromin 2 | 1 | 2015 | 40 | 0.530 |
Why?
|
| Klatskin Tumor | 1 | 2015 | 29 | 0.530 |
Why?
|
| Disease Models, Animal | 11 | 2018 | 7218 | 0.520 |
Why?
|
| Methylation | 4 | 2020 | 591 | 0.520 |
Why?
|
| Wnt Signaling Pathway | 2 | 2015 | 428 | 0.520 |
Why?
|
| beta Catenin | 3 | 2014 | 687 | 0.510 |
Why?
|
| Norepinephrine | 2 | 2013 | 272 | 0.510 |
Why?
|
| Thyroid Hormones | 1 | 2015 | 111 | 0.510 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2022 | 1219 | 0.510 |
Why?
|
| Transplantation, Heterologous | 8 | 2014 | 1077 | 0.500 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2023 | 5183 | 0.500 |
Why?
|
| Mice, Inbred C57BL | 16 | 2020 | 6927 | 0.490 |
Why?
|
| Cell Division | 13 | 2011 | 2467 | 0.490 |
Why?
|
| Chromatin Immunoprecipitation | 6 | 2014 | 511 | 0.480 |
Why?
|
| MicroRNAs | 5 | 2017 | 2955 | 0.480 |
Why?
|
| Gene Expression Regulation, Enzymologic | 5 | 2014 | 696 | 0.480 |
Why?
|
| Trans-Activators | 6 | 2015 | 1557 | 0.480 |
Why?
|
| Real-Time Polymerase Chain Reaction | 5 | 2015 | 1221 | 0.480 |
Why?
|
| Pancreatic Stellate Cells | 1 | 2014 | 78 | 0.470 |
Why?
|
| Lamin Type B | 1 | 2013 | 9 | 0.470 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2014 | 71 | 0.460 |
Why?
|
| Caveolin 1 | 2 | 2011 | 203 | 0.460 |
Why?
|
| Neoplasms, Experimental | 5 | 2011 | 745 | 0.460 |
Why?
|
| Paracrine Communication | 1 | 2014 | 129 | 0.460 |
Why?
|
| Prognosis | 22 | 2018 | 21737 | 0.460 |
Why?
|
| Heat-Shock Proteins | 2 | 2006 | 311 | 0.450 |
Why?
|
| Hedgehog Proteins | 2 | 2014 | 423 | 0.450 |
Why?
|
| Neoplasm Proteins | 7 | 2018 | 3233 | 0.440 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2015 | 3632 | 0.440 |
Why?
|
| Smad4 Protein | 1 | 2014 | 196 | 0.440 |
Why?
|
| Protein Binding | 8 | 2020 | 3438 | 0.440 |
Why?
|
| Mitochondria | 1 | 2019 | 1281 | 0.430 |
Why?
|
| Tumor Microenvironment | 8 | 2023 | 2860 | 0.420 |
Why?
|
| Cell Hypoxia | 4 | 2002 | 329 | 0.420 |
Why?
|
| Interferon-beta | 4 | 2001 | 102 | 0.420 |
Why?
|
| Pyloric Antrum | 1 | 2011 | 60 | 0.410 |
Why?
|
| Cell Cycle | 9 | 2018 | 2085 | 0.410 |
Why?
|
| RNA Interference | 6 | 2018 | 1411 | 0.400 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2004 | 1064 | 0.390 |
Why?
|
| Down-Regulation | 8 | 2014 | 2078 | 0.380 |
Why?
|
| Glioblastoma | 6 | 2023 | 1799 | 0.360 |
Why?
|
| Cell Culture Techniques | 1 | 2013 | 598 | 0.360 |
Why?
|
| NF-kappa B | 6 | 2005 | 1551 | 0.350 |
Why?
|
| Lymphatic Metastasis | 10 | 2012 | 4845 | 0.350 |
Why?
|
| Melanoma, Experimental | 6 | 2001 | 367 | 0.350 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2009 | 136 | 0.340 |
Why?
|
| Drug Synergism | 5 | 2011 | 1316 | 0.340 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2015 | 2028 | 0.340 |
Why?
|
| Neoplasms | 10 | 2023 | 15180 | 0.330 |
Why?
|
| Carrier Proteins | 3 | 2015 | 2022 | 0.330 |
Why?
|
| Microfilament Proteins | 1 | 2011 | 488 | 0.330 |
Why?
|
| Neoplasm Staging | 13 | 2018 | 13669 | 0.330 |
Why?
|
| Amino Acid Oxidoreductases | 4 | 1995 | 24 | 0.320 |
Why?
|
| Annexin A1 | 1 | 2008 | 39 | 0.320 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2016 | 1826 | 0.320 |
Why?
|
| Electrophoretic Mobility Shift Assay | 5 | 2008 | 190 | 0.310 |
Why?
|
| Male | 41 | 2020 | 123338 | 0.310 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2008 | 286 | 0.310 |
Why?
|
| Transcription Factor AP-1 | 5 | 2002 | 244 | 0.310 |
Why?
|
| Interferon-gamma | 9 | 2012 | 1148 | 0.310 |
Why?
|
| Brain Neoplasms | 10 | 2017 | 4838 | 0.300 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2009 | 170 | 0.300 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2015 | 15874 | 0.300 |
Why?
|
| Green Fluorescent Proteins | 1 | 2009 | 694 | 0.300 |
Why?
|
| Biomarkers, Tumor | 8 | 2018 | 10348 | 0.300 |
Why?
|
| Gene Expression Profiling | 5 | 2018 | 5155 | 0.300 |
Why?
|
| Melanoma | 11 | 2008 | 5319 | 0.300 |
Why?
|
| Glioma | 5 | 2023 | 1940 | 0.290 |
Why?
|
| Endothelial Cells | 3 | 2015 | 1046 | 0.280 |
Why?
|
| Blotting, Northern | 6 | 2008 | 672 | 0.280 |
Why?
|
| Transcriptome | 1 | 2015 | 1863 | 0.280 |
Why?
|
| Immunoenzyme Techniques | 3 | 2014 | 1165 | 0.280 |
Why?
|
| Middle Aged | 30 | 2020 | 86544 | 0.280 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 3550 | 0.270 |
Why?
|
| RNA Stability | 3 | 2020 | 126 | 0.270 |
Why?
|
| Glucose-6-Phosphate Isomerase | 1 | 2005 | 24 | 0.270 |
Why?
|
| Molecular Chaperones | 1 | 2006 | 259 | 0.260 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2009 | 436 | 0.260 |
Why?
|
| Antibodies, Monoclonal | 3 | 2008 | 4386 | 0.260 |
Why?
|
| Isoenzymes | 3 | 2014 | 608 | 0.260 |
Why?
|
| Carcinoma, Papillary | 1 | 2009 | 584 | 0.250 |
Why?
|
| Cell Survival | 6 | 2019 | 3042 | 0.250 |
Why?
|
| Protein Kinases | 1 | 2009 | 875 | 0.240 |
Why?
|
| Time Factors | 11 | 2015 | 12984 | 0.240 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2005 | 185 | 0.240 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 1 | 2023 | 25 | 0.240 |
Why?
|
| Cadherins | 3 | 2016 | 663 | 0.240 |
Why?
|
| Hypoxia | 2 | 2023 | 448 | 0.230 |
Why?
|
| Cell Growth Processes | 4 | 2011 | 342 | 0.230 |
Why?
|
| Vascular Endothelial Growth Factors | 7 | 2003 | 212 | 0.230 |
Why?
|
| Fibrosis | 2 | 2023 | 767 | 0.230 |
Why?
|
| RNA | 2 | 2018 | 1010 | 0.230 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2004 | 177 | 0.230 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2015 | 2504 | 0.220 |
Why?
|
| DNA Primers | 5 | 2008 | 1395 | 0.220 |
Why?
|
| Molecular Epidemiology | 1 | 2004 | 246 | 0.220 |
Why?
|
| Hepatitis B virus | 1 | 2005 | 215 | 0.220 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2001 | 586 | 0.220 |
Why?
|
| Pentacyclic Triterpenes | 2 | 2013 | 14 | 0.220 |
Why?
|
| Breast Neoplasms | 4 | 2022 | 15709 | 0.220 |
Why?
|
| Microcirculation | 1 | 2023 | 200 | 0.220 |
Why?
|
| Mice, Inbred C3H | 9 | 1999 | 380 | 0.210 |
Why?
|
| Macrophages | 10 | 2003 | 1313 | 0.210 |
Why?
|
| Colorectal Neoplasms | 3 | 2023 | 3583 | 0.210 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2004 | 347 | 0.200 |
Why?
|
| Fibrosarcoma | 2 | 1999 | 134 | 0.200 |
Why?
|
| GTPase-Activating Proteins | 1 | 2022 | 127 | 0.200 |
Why?
|
| Aged | 18 | 2020 | 70367 | 0.200 |
Why?
|
| Specific Pathogen-Free Organisms | 3 | 2016 | 93 | 0.200 |
Why?
|
| Gene Expression Regulation | 5 | 2008 | 4027 | 0.190 |
Why?
|
| Enzyme Induction | 7 | 1999 | 248 | 0.190 |
Why?
|
| Enzyme Activation | 4 | 2018 | 1760 | 0.190 |
Why?
|
| Phosphorylation | 6 | 2016 | 4809 | 0.190 |
Why?
|
| Heparin | 1 | 2023 | 362 | 0.190 |
Why?
|
| Loss of Heterozygosity | 1 | 2003 | 603 | 0.190 |
Why?
|
| Stress, Physiological | 2 | 2019 | 497 | 0.190 |
Why?
|
| Immunoprecipitation | 2 | 2015 | 591 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2015 | 10067 | 0.180 |
Why?
|
| Models, Animal | 1 | 2003 | 664 | 0.180 |
Why?
|
| Genome, Human | 1 | 2008 | 1868 | 0.180 |
Why?
|
| Liver Neoplasms, Experimental | 3 | 2001 | 186 | 0.170 |
Why?
|
| Genes, Reporter | 3 | 2018 | 798 | 0.170 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2003 | 645 | 0.170 |
Why?
|
| Base Sequence | 5 | 2013 | 4886 | 0.170 |
Why?
|
| Tumor Burden | 4 | 2015 | 1991 | 0.170 |
Why?
|
| Pleural Effusion | 1 | 2001 | 201 | 0.170 |
Why?
|
| Gene Expression | 5 | 2017 | 3563 | 0.170 |
Why?
|
| LIM Domain Proteins | 1 | 2019 | 106 | 0.160 |
Why?
|
| Transcription Elongation, Genetic | 1 | 2018 | 25 | 0.160 |
Why?
|
| Cell Differentiation | 4 | 2015 | 4043 | 0.160 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2020 | 210 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2023 | 2062 | 0.160 |
Why?
|
| Flow Cytometry | 2 | 2015 | 3022 | 0.160 |
Why?
|
| Mice, Knockout | 5 | 2011 | 5672 | 0.160 |
Why?
|
| Genes, p53 | 2 | 2001 | 1093 | 0.160 |
Why?
|
| Endopeptidases | 2 | 2016 | 220 | 0.160 |
Why?
|
| Cytokines | 2 | 2018 | 2824 | 0.160 |
Why?
|
| Bevacizumab | 4 | 2015 | 938 | 0.160 |
Why?
|
| Peptides | 2 | 2018 | 1476 | 0.160 |
Why?
|
| Liver Cirrhosis | 1 | 2005 | 945 | 0.150 |
Why?
|
| Chronic Disease | 1 | 2023 | 1850 | 0.150 |
Why?
|
| AlkB Homolog 5, RNA Demethylase | 1 | 2017 | 4 | 0.150 |
Why?
|
| Anticoagulants | 1 | 2023 | 791 | 0.150 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2017 | 83 | 0.150 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2003 | 1485 | 0.150 |
Why?
|
| Phenotype | 7 | 2022 | 6255 | 0.150 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2018 | 1557 | 0.140 |
Why?
|
| Drosophila Proteins | 1 | 2003 | 857 | 0.140 |
Why?
|
| Cell Dedifferentiation | 1 | 2017 | 96 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2014 | 4945 | 0.140 |
Why?
|
| Survival Rate | 6 | 2014 | 12239 | 0.140 |
Why?
|
| Thiolester Hydrolases | 1 | 2016 | 34 | 0.140 |
Why?
|
| Nitric Oxide Donors | 2 | 2010 | 50 | 0.140 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2016 | 232 | 0.140 |
Why?
|
| Adenosine | 1 | 2018 | 291 | 0.140 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2016 | 163 | 0.140 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2020 | 797 | 0.140 |
Why?
|
| Hep G2 Cells | 2 | 2015 | 155 | 0.140 |
Why?
|
| Hepatocyte Nuclear Factor 6 | 1 | 2015 | 6 | 0.140 |
Why?
|
| Adjuvants, Immunologic | 2 | 2000 | 661 | 0.130 |
Why?
|
| Binding Sites | 4 | 2015 | 2170 | 0.130 |
Why?
|
| Hexokinase | 1 | 2015 | 36 | 0.130 |
Why?
|
| Syndecan-2 | 1 | 2015 | 15 | 0.130 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2015 | 1541 | 0.130 |
Why?
|
| Oxygen | 2 | 2019 | 755 | 0.130 |
Why?
|
| BALB 3T3 Cells | 1 | 2014 | 5 | 0.130 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2015 | 1266 | 0.130 |
Why?
|
| Histone Demethylases | 1 | 2016 | 144 | 0.130 |
Why?
|
| Perfusion Imaging | 1 | 2015 | 30 | 0.130 |
Why?
|
| Oncogenes | 3 | 2018 | 669 | 0.130 |
Why?
|
| RNA, Neoplasm | 4 | 2018 | 773 | 0.130 |
Why?
|
| Tyrphostins | 1 | 2015 | 107 | 0.130 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2015 | 87 | 0.130 |
Why?
|
| Sulfonamides | 1 | 2004 | 1826 | 0.130 |
Why?
|
| Histones | 2 | 2019 | 1462 | 0.130 |
Why?
|
| Lipopolysaccharides | 6 | 2001 | 559 | 0.120 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2015 | 157 | 0.120 |
Why?
|
| Deoxycytidine | 2 | 2014 | 1360 | 0.120 |
Why?
|
| China | 2 | 2008 | 613 | 0.120 |
Why?
|
| Gene Silencing | 1 | 2017 | 835 | 0.120 |
Why?
|
| Cell Death | 3 | 2006 | 672 | 0.120 |
Why?
|
| Survival Analysis | 6 | 2018 | 9195 | 0.120 |
Why?
|
| Karyopherins | 1 | 2015 | 135 | 0.120 |
Why?
|
| alpha-Fetoproteins | 1 | 2015 | 232 | 0.120 |
Why?
|
| Biomarkers | 2 | 2022 | 5055 | 0.120 |
Why?
|
| Oligopeptides | 2 | 1995 | 425 | 0.120 |
Why?
|
| Multidetector Computed Tomography | 1 | 2015 | 151 | 0.110 |
Why?
|
| Genetic Vectors | 5 | 2005 | 1681 | 0.110 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2019 | 1435 | 0.110 |
Why?
|
| Recombinant Proteins | 5 | 2001 | 2915 | 0.110 |
Why?
|
| Collagen | 2 | 2011 | 737 | 0.110 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2014 | 321 | 0.110 |
Why?
|
| Free Radicals | 2 | 2003 | 62 | 0.110 |
Why?
|
| HEK293 Cells | 1 | 2017 | 1498 | 0.110 |
Why?
|
| Cell Communication | 2 | 2015 | 504 | 0.110 |
Why?
|
| Cells, Cultured | 3 | 2009 | 5598 | 0.110 |
Why?
|
| Immunotherapy | 2 | 2023 | 3347 | 0.110 |
Why?
|
| Cell Nucleus | 4 | 2007 | 1618 | 0.110 |
Why?
|
| Genes, ras | 1 | 2016 | 667 | 0.110 |
Why?
|
| Mice, Transgenic | 2 | 2011 | 4126 | 0.110 |
Why?
|
| DNA Repair | 2 | 1998 | 1870 | 0.110 |
Why?
|
| Wnt Proteins | 2 | 2012 | 397 | 0.110 |
Why?
|
| Vitamin D | 1 | 2015 | 260 | 0.110 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 2 | 2011 | 62 | 0.110 |
Why?
|
| Cyclin D1 | 4 | 2010 | 577 | 0.110 |
Why?
|
| B7-1 Antigen | 1 | 2012 | 88 | 0.110 |
Why?
|
| Repressor Proteins | 1 | 2020 | 1663 | 0.110 |
Why?
|
| Response Elements | 2 | 2004 | 194 | 0.100 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2012 | 68 | 0.100 |
Why?
|
| Methylnitrosourea | 1 | 2011 | 46 | 0.100 |
Why?
|
| Proportional Hazards Models | 3 | 2011 | 5009 | 0.100 |
Why?
|
| Organ Culture Techniques | 1 | 2013 | 245 | 0.100 |
Why?
|
| Lung Neoplasms | 11 | 2013 | 11571 | 0.100 |
Why?
|
| Microsatellite Repeats | 2 | 2005 | 576 | 0.100 |
Why?
|
| Disease-Free Survival | 6 | 2018 | 10021 | 0.100 |
Why?
|
| Receptor Cross-Talk | 1 | 2012 | 79 | 0.100 |
Why?
|
| Fibroblasts | 3 | 2002 | 1642 | 0.100 |
Why?
|
| Sympathetic Nervous System | 1 | 2013 | 159 | 0.100 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2012 | 234 | 0.100 |
Why?
|
| Nuclear Proteins | 5 | 2023 | 3317 | 0.100 |
Why?
|
| Genetic Therapy | 4 | 2001 | 1601 | 0.100 |
Why?
|
| Metformin | 1 | 2015 | 378 | 0.100 |
Why?
|
| Sequence Deletion | 2 | 2018 | 874 | 0.100 |
Why?
|
| Laminin | 1 | 2011 | 196 | 0.100 |
Why?
|
| Adult | 11 | 2015 | 78179 | 0.100 |
Why?
|
| Viral Regulatory and Accessory Proteins | 2 | 2015 | 63 | 0.100 |
Why?
|
| Carcinoma, Renal Cell | 3 | 1998 | 2321 | 0.100 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2015 | 584 | 0.090 |
Why?
|
| Sirolimus | 1 | 2015 | 818 | 0.090 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2014 | 724 | 0.090 |
Why?
|
| Proteoglycans | 1 | 2011 | 255 | 0.090 |
Why?
|
| Peptide Fragments | 2 | 1995 | 1265 | 0.090 |
Why?
|
| Adrenergic beta-1 Receptor Agonists | 1 | 2009 | 4 | 0.090 |
Why?
|
| ortho-Aminobenzoates | 1 | 2010 | 19 | 0.090 |
Why?
|
| Acidosis | 2 | 2003 | 117 | 0.090 |
Why?
|
| Integrases | 1 | 2011 | 262 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2004 | 5538 | 0.090 |
Why?
|
| Endosomal Sorting Complexes Required for Transport | 1 | 2010 | 61 | 0.090 |
Why?
|
| Cell Adhesion | 1 | 2013 | 1001 | 0.090 |
Why?
|
| Zinc Finger Protein GLI1 | 2 | 2015 | 108 | 0.090 |
Why?
|
| Macrophages, Peritoneal | 3 | 2001 | 68 | 0.090 |
Why?
|
| Kidney Neoplasms | 3 | 1998 | 3018 | 0.090 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 12 | 1 | 2009 | 32 | 0.090 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2011 | 566 | 0.090 |
Why?
|
| Drug Combinations | 1 | 2011 | 621 | 0.090 |
Why?
|
| Peptidylprolyl Isomerase | 1 | 2009 | 73 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2009 | 260 | 0.080 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1995 | 1041 | 0.080 |
Why?
|
| Hyperglycemia | 1 | 2012 | 332 | 0.080 |
Why?
|
| Fibroblast Growth Factor 2 | 3 | 2008 | 222 | 0.080 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2009 | 236 | 0.080 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2009 | 106 | 0.080 |
Why?
|
| Retroviridae | 3 | 1998 | 323 | 0.080 |
Why?
|
| Neuroendocrine Tumors | 1 | 2015 | 634 | 0.080 |
Why?
|
| Nitrites | 2 | 2001 | 61 | 0.080 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2009 | 162 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2009 | 279 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 6223 | 0.080 |
Why?
|
| Adenoviridae | 2 | 2005 | 1432 | 0.080 |
Why?
|
| Pyridines | 1 | 2015 | 1243 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2008 | 3263 | 0.080 |
Why?
|
| 3' Untranslated Regions | 2 | 2017 | 345 | 0.080 |
Why?
|
| Case-Control Studies | 1 | 2018 | 6104 | 0.080 |
Why?
|
| Antigens, CD | 2 | 2016 | 1382 | 0.080 |
Why?
|
| Early Detection of Cancer | 1 | 2016 | 1267 | 0.080 |
Why?
|
| Cisplatin | 1 | 2015 | 2432 | 0.080 |
Why?
|
| Tumor Virus Infections | 1 | 2009 | 217 | 0.070 |
Why?
|
| Carcinogenicity Tests | 3 | 2003 | 70 | 0.070 |
Why?
|
| Alternative Splicing | 1 | 2010 | 581 | 0.070 |
Why?
|
| Computational Biology | 2 | 2016 | 1270 | 0.070 |
Why?
|
| Antigens, CD34 | 2 | 2005 | 593 | 0.070 |
Why?
|
| Epigenesis, Genetic | 2 | 2017 | 1397 | 0.070 |
Why?
|
| Astrocytes | 1 | 2010 | 365 | 0.070 |
Why?
|
| Mutagenesis | 1 | 2008 | 478 | 0.070 |
Why?
|
| Phosphoproteins | 2 | 2023 | 1151 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2009 | 640 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 2 | 2014 | 2334 | 0.070 |
Why?
|
| DNA | 2 | 2005 | 2683 | 0.070 |
Why?
|
| In Vitro Techniques | 2 | 2007 | 1614 | 0.070 |
Why?
|
| omega-N-Methylarginine | 2 | 1995 | 34 | 0.070 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2006 | 107 | 0.070 |
Why?
|
| B7-H1 Antigen | 1 | 2012 | 1024 | 0.070 |
Why?
|
| Transduction, Genetic | 1 | 2006 | 463 | 0.060 |
Why?
|
| Liver | 1 | 2015 | 2904 | 0.060 |
Why?
|
| Fatty Acid Desaturases | 1 | 2005 | 14 | 0.060 |
Why?
|
| Point Mutation | 1 | 2008 | 769 | 0.060 |
Why?
|
| Cyclin A | 1 | 2005 | 45 | 0.060 |
Why?
|
| Genes, Dominant | 2 | 2003 | 330 | 0.060 |
Why?
|
| Cell Line | 4 | 2018 | 5071 | 0.060 |
Why?
|
| Body Weight | 1 | 2010 | 1292 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2018 | 4768 | 0.060 |
Why?
|
| ras Proteins | 1 | 2009 | 771 | 0.060 |
Why?
|
| DNA Methylation | 2 | 2005 | 2671 | 0.060 |
Why?
|
| Molecular Sequence Data | 3 | 2011 | 6062 | 0.060 |
Why?
|
| Blotting, Southern | 1 | 2005 | 399 | 0.060 |
Why?
|
| Genes, p16 | 1 | 2005 | 124 | 0.060 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2010 | 853 | 0.060 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2005 | 446 | 0.060 |
Why?
|
| Macrophage Activation | 3 | 2001 | 146 | 0.060 |
Why?
|
| Carcinoid Tumor | 1 | 2007 | 280 | 0.060 |
Why?
|
| Antineoplastic Agents | 6 | 2019 | 14288 | 0.060 |
Why?
|
| Endothelium, Vascular | 1 | 2009 | 875 | 0.060 |
Why?
|
| Herpesvirus 4, Human | 1 | 2009 | 968 | 0.060 |
Why?
|
| Arabidopsis Proteins | 1 | 2005 | 84 | 0.060 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2009 | 491 | 0.060 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2004 | 136 | 0.060 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2005 | 267 | 0.060 |
Why?
|
| Celecoxib | 1 | 2004 | 201 | 0.060 |
Why?
|
| Glycoproteins | 1 | 2007 | 746 | 0.060 |
Why?
|
| DNA, Complementary | 1 | 2005 | 870 | 0.060 |
Why?
|
| Astrocytoma | 1 | 2006 | 322 | 0.060 |
Why?
|
| Genotype | 1 | 2011 | 4104 | 0.060 |
Why?
|
| Retinoblastoma Protein | 1 | 2005 | 330 | 0.060 |
Why?
|
| I-kappa B Proteins | 1 | 2004 | 170 | 0.060 |
Why?
|
| Interleukin-1 | 4 | 1997 | 455 | 0.060 |
Why?
|
| Smad Proteins | 1 | 2003 | 88 | 0.060 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2023 | 66 | 0.060 |
Why?
|
| Collagenases | 2 | 2000 | 74 | 0.050 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2023 | 986 | 0.050 |
Why?
|
| Embryo, Nonmammalian | 1 | 2003 | 232 | 0.050 |
Why?
|
| T-Lymphoma Invasion and Metastasis-inducing Protein 1 | 1 | 2022 | 24 | 0.050 |
Why?
|
| Caspases | 1 | 2005 | 662 | 0.050 |
Why?
|
| CpG Islands | 1 | 2005 | 631 | 0.050 |
Why?
|
| DNA, Viral | 1 | 2005 | 675 | 0.050 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2004 | 355 | 0.050 |
Why?
|
| Mutation | 4 | 2015 | 15167 | 0.050 |
Why?
|
| Ribosomes | 1 | 2023 | 147 | 0.050 |
Why?
|
| Morphogenesis | 1 | 2003 | 337 | 0.050 |
Why?
|
| Models, Biological | 2 | 2019 | 3242 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 4903 | 0.050 |
Why?
|
| Genomic Instability | 1 | 2005 | 517 | 0.050 |
Why?
|
| Sp3 Transcription Factor | 1 | 2001 | 13 | 0.050 |
Why?
|
| Oncogene Proteins | 1 | 2003 | 356 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2002 | 165 | 0.050 |
Why?
|
| Acids | 1 | 2001 | 38 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 1 | 2005 | 1487 | 0.050 |
Why?
|
| Exons | 1 | 2005 | 1325 | 0.050 |
Why?
|
| Cathepsins | 2 | 1998 | 46 | 0.050 |
Why?
|
| ErbB Receptors | 1 | 2009 | 2297 | 0.050 |
Why?
|
| Liposomes | 3 | 2001 | 680 | 0.050 |
Why?
|
| Mesocricetus | 1 | 2001 | 114 | 0.050 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2007 | 716 | 0.050 |
Why?
|
| Growth Inhibitors | 1 | 2001 | 149 | 0.050 |
Why?
|
| CCAAT-Enhancer-Binding Protein-beta | 1 | 2000 | 51 | 0.050 |
Why?
|
| Extracellular Space | 1 | 2000 | 131 | 0.050 |
Why?
|
| Suppressor of Cytokine Signaling 1 Protein | 2 | 2011 | 19 | 0.050 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 1999 | 43 | 0.040 |
Why?
|
| Cricetinae | 1 | 2001 | 702 | 0.040 |
Why?
|
| Mice, Mutant Strains | 1 | 2001 | 623 | 0.040 |
Why?
|
| Metalloendopeptidases | 1 | 2000 | 179 | 0.040 |
Why?
|
| Complement C3 | 2 | 1998 | 75 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2004 | 4323 | 0.040 |
Why?
|
| 3T3 Cells | 2 | 1996 | 353 | 0.040 |
Why?
|
| Tissue Distribution | 2 | 2018 | 877 | 0.040 |
Why?
|
| Kidney | 1 | 2008 | 2144 | 0.040 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1999 | 257 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2004 | 2325 | 0.040 |
Why?
|
| Fructose-Bisphosphatase | 1 | 2018 | 7 | 0.040 |
Why?
|
| Genome | 1 | 2003 | 678 | 0.040 |
Why?
|
| DNA Replication | 1 | 2023 | 746 | 0.040 |
Why?
|
| Lipoproteins | 1 | 2000 | 252 | 0.040 |
Why?
|
| Enzyme Precursors | 1 | 1998 | 66 | 0.040 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 1998 | 82 | 0.040 |
Why?
|
| Drosophila | 1 | 2003 | 839 | 0.040 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 1998 | 673 | 0.040 |
Why?
|
| Piperazines | 1 | 2007 | 2098 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2001 | 1487 | 0.040 |
Why?
|
| Chemokine CCL2 | 2 | 1995 | 196 | 0.040 |
Why?
|
| ELAV-Like Protein 1 | 1 | 2017 | 18 | 0.040 |
Why?
|
| Genetic Engineering | 2 | 1998 | 287 | 0.040 |
Why?
|
| Calcium | 2 | 2002 | 1545 | 0.040 |
Why?
|
| DNA Fragmentation | 1 | 1997 | 196 | 0.040 |
Why?
|
| S-Nitroso-N-Acetylpenicillamine | 1 | 1996 | 16 | 0.040 |
Why?
|
| Spheroids, Cellular | 1 | 2018 | 221 | 0.040 |
Why?
|
| Penicillamine | 1 | 1996 | 22 | 0.040 |
Why?
|
| Biopsy | 1 | 2005 | 3447 | 0.040 |
Why?
|
| Nitroprusside | 1 | 1996 | 49 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2023 | 1684 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2003 | 3189 | 0.040 |
Why?
|
| Cell Cycle Proteins | 2 | 2002 | 2053 | 0.040 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2007 | 69 | 0.040 |
Why?
|
| Hyaluronic Acid | 1 | 2018 | 165 | 0.040 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1999 | 389 | 0.030 |
Why?
|
| Thiadiazoles | 1 | 2016 | 47 | 0.030 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1996 | 223 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 1596 | 0.030 |
Why?
|
| Nitrates | 1 | 1995 | 43 | 0.030 |
Why?
|
| Suppression, Genetic | 1 | 1995 | 67 | 0.030 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 1998 | 625 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2004 | 1479 | 0.030 |
Why?
|
| Age Factors | 1 | 2005 | 5384 | 0.030 |
Why?
|
| Autocrine Communication | 1 | 2015 | 84 | 0.030 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2016 | 216 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2018 | 746 | 0.030 |
Why?
|
| Chemotactic Factors | 1 | 1994 | 42 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 2019 | 888 | 0.030 |
Why?
|
| Cysteine Endopeptidases | 1 | 1996 | 250 | 0.030 |
Why?
|
| Feedback, Physiological | 1 | 2015 | 193 | 0.030 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 1995 | 214 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2007 | 3538 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2017 | 1077 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 1996 | 485 | 0.030 |
Why?
|
| Drug Carriers | 1 | 1995 | 327 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2015 | 271 | 0.030 |
Why?
|
| Drug Interactions | 1 | 1995 | 555 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2016 | 579 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 2015 | 475 | 0.030 |
Why?
|
| Skin Neoplasms | 3 | 2006 | 4655 | 0.030 |
Why?
|
| Ovarian Neoplasms | 2 | 1999 | 4660 | 0.030 |
Why?
|
| Triazoles | 1 | 1997 | 618 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2019 | 994 | 0.030 |
Why?
|
| Receptors, Adrenergic | 1 | 2012 | 49 | 0.030 |
Why?
|
| Receptors, Interferon | 1 | 2012 | 45 | 0.030 |
Why?
|
| Everolimus | 1 | 2015 | 415 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 1750 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2015 | 33028 | 0.030 |
Why?
|
| Indoles | 1 | 2017 | 1011 | 0.020 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 1996 | 608 | 0.020 |
Why?
|
| Azacitidine | 1 | 2016 | 1149 | 0.020 |
Why?
|
| Nedd4 Ubiquitin Protein Ligases | 1 | 2010 | 23 | 0.020 |
Why?
|
| Oncogene Protein v-akt | 1 | 2010 | 102 | 0.020 |
Why?
|
| NIMA-Interacting Peptidylprolyl Isomerase | 1 | 2009 | 60 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2010 | 202 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2009 | 261 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 3482 | 0.020 |
Why?
|
| Viral Matrix Proteins | 1 | 2009 | 201 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2009 | 521 | 0.020 |
Why?
|
| Cyclin E | 1 | 2010 | 266 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 1996 | 4976 | 0.020 |
Why?
|
| Serine | 1 | 2009 | 388 | 0.020 |
Why?
|
| Tyrosine | 1 | 2009 | 500 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2009 | 29996 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2009 | 882 | 0.020 |
Why?
|
| AC133 Antigen | 1 | 2007 | 111 | 0.020 |
Why?
|
| Cathepsin L | 2 | 1998 | 25 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2008 | 606 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2010 | 529 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2009 | 1033 | 0.020 |
Why?
|
| Doxorubicin | 1 | 1994 | 3005 | 0.020 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2006 | 51 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2009 | 667 | 0.020 |
Why?
|
| Bone Marrow | 1 | 1994 | 2360 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1993 | 1759 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 1996 | 1540 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2018 | 9282 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2012 | 1129 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2006 | 256 | 0.020 |
Why?
|
| Carcinoma | 1 | 1996 | 2582 | 0.020 |
Why?
|
| Cell Transplantation | 2 | 1995 | 84 | 0.020 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2005 | 206 | 0.020 |
Why?
|
| Janus Kinase 2 | 1 | 2008 | 680 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2007 | 706 | 0.020 |
Why?
|
| Texas | 1 | 2015 | 6308 | 0.010 |
Why?
|
| Risk Factors | 3 | 2009 | 17622 | 0.010 |
Why?
|
| Spleen | 2 | 1998 | 674 | 0.010 |
Why?
|
| Young Adult | 2 | 2015 | 21494 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2012 | 1066 | 0.010 |
Why?
|
| Age of Onset | 1 | 2005 | 826 | 0.010 |
Why?
|
| Imatinib Mesylate | 1 | 2007 | 1665 | 0.010 |
Why?
|
| Intracellular Fluid | 1 | 2002 | 45 | 0.010 |
Why?
|
| Ionophores | 1 | 2002 | 22 | 0.010 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2002 | 56 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2007 | 14913 | 0.010 |
Why?
|
| Tumor Suppressor p53-Binding Protein 1 | 1 | 2001 | 87 | 0.010 |
Why?
|
| NFATC Transcription Factors | 1 | 2002 | 99 | 0.010 |
Why?
|
| Indians, North American | 1 | 2002 | 87 | 0.010 |
Why?
|
| Benzamides | 1 | 2007 | 1834 | 0.010 |
Why?
|
| Matrix Metalloproteinase 12 | 1 | 2000 | 18 | 0.010 |
Why?
|
| Densitometry | 1 | 2000 | 45 | 0.010 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2000 | 43 | 0.010 |
Why?
|
| Exudates and Transudates | 1 | 2000 | 52 | 0.010 |
Why?
|
| Indicators and Reagents | 1 | 2000 | 128 | 0.010 |
Why?
|
| Lipopeptides | 1 | 2000 | 114 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1999 | 300 | 0.010 |
Why?
|
| Culture Media | 1 | 2000 | 320 | 0.010 |
Why?
|
| Half-Life | 1 | 1999 | 258 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2005 | 1905 | 0.010 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 4 | 1 | 1998 | 3 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 1330 | 0.010 |
Why?
|
| Luciferases | 1 | 1999 | 444 | 0.010 |
Why?
|
| United States | 2 | 2009 | 15574 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2004 | 2325 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 1997 | 111 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2005 | 1491 | 0.010 |
Why?
|
| Sex Factors | 1 | 2002 | 2156 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 1996 | 261 | 0.010 |
Why?
|
| Protein Phosphatase 1 | 1 | 1995 | 79 | 0.010 |
Why?
|
| Transplantation, Isogeneic | 1 | 1995 | 59 | 0.010 |
Why?
|
| Cell Count | 1 | 1996 | 507 | 0.010 |
Why?
|
| Clone Cells | 1 | 1997 | 547 | 0.010 |
Why?
|
| Skin Physiological Phenomena | 1 | 1995 | 42 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 1995 | 391 | 0.010 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 1996 | 358 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 1997 | 573 | 0.010 |
Why?
|
| Logistic Models | 1 | 2002 | 3450 | 0.010 |
Why?
|
| Keratinocytes | 1 | 1995 | 241 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2009 | 38011 | 0.010 |
Why?
|
| Idoxuridine | 1 | 1994 | 17 | 0.010 |
Why?
|
| Quinones | 1 | 1993 | 21 | 0.010 |
Why?
|
| Mice, SCID | 1 | 1998 | 1865 | 0.010 |
Why?
|
| Rifabutin | 1 | 1993 | 25 | 0.010 |
Why?
|
| Organ Specificity | 1 | 1995 | 695 | 0.010 |
Why?
|
| Genistein | 1 | 1993 | 73 | 0.010 |
Why?
|
| Lactams, Macrocyclic | 1 | 1993 | 90 | 0.010 |
Why?
|
| Epitopes | 1 | 1996 | 682 | 0.010 |
Why?
|
| Benzoquinones | 1 | 1993 | 108 | 0.010 |
Why?
|
| Isoflavones | 1 | 1993 | 73 | 0.010 |
Why?
|
| Bone Marrow Diseases | 1 | 1994 | 174 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 1998 | 907 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1994 | 683 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1994 | 588 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 1996 | 1031 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 1994 | 373 | 0.010 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 1996 | 994 | 0.010 |
Why?
|
| Adaptation, Psychological | 1 | 1995 | 772 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 1995 | 1109 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1995 | 4231 | 0.010 |
Why?
|
| Lung | 1 | 1995 | 3167 | 0.000 |
Why?
|
| Immunotherapy, Adoptive | 1 | 1994 | 1765 | 0.000 |
Why?
|